LeonaBio hits 500 patients, $146M potential warrant cash
Rhea-AI Filing Summary
LeonaBio, Inc. (LONA) reported enrollment of the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial of lasofoxifene in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after progression on aromatase inhibitors and CDK4/6 inhibitors.
LeonaBio previously issued 23,031,494 Series A Common Warrants in a December 2025 private placement, each with an exercise price of $6.35 per share, generally payable in cash unless a resale registration statement is unavailable, in which case they may be exercised on a cashless net basis. The warrants become exercisable at each holder’s option after the earlier of (1) the latest of June 30, 2026, the publicly announced ELAINE-3 Enrollment Date, and specified FDA action on Eli Lilly’s imlunestrant plus abemaciclib application, and (2) October 31, 2026, and remain exercisable for 30 days, no later than November 30, 2026. If exercised in full for cash, they would provide approximately $146.2 million of additional capital.
Positive
- 500th patient enrolled in Phase 3 ELAINE-3 trial, marking a significant clinical milestone for lasofoxifene plus abemaciclib in a targeted metastatic breast cancer population.
- Potential $146.2 million capital inflow if all 23,031,494 Series A Common Warrants are exercised for cash at $6.35 per share, enhancing LeonaBio’s funding flexibility.
Negative
- Warrant proceeds are uncertain, as some or all Series A Common Warrants may expire unexercised or be exercised on a cashless basis, which could result in reduced or no cash inflows.
- Clinical and regulatory outcomes are uncertain for both the ELAINE-3 trial and third-party products such as imlunestrant, which could affect timelines and value realization.
Filing Explained
The disclosed approximately
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
ELAINE-3 trial enrollment milestone: 500 subjects
Series A Common Warrants issued: 23,031,494 warrants
Series A Common Warrant exercise price: $6.35 per share
+4 more
7 metrics
ELAINE-3 trial enrollment milestone
500 subjects
Enrollment milestone reached in Phase 3 ELAINE-3 trial
Series A Common Warrants issued
23,031,494 warrants
Warrants issued in December 2025 private placement
Series A Common Warrant exercise price
$6.35 per share
Cash exercise price per share of common stock
Potential proceeds from full Series A Warrant exercise
$146.2 million
Approximate additional capital if all Series A Warrants are exercised for cash
Latest date for Initial Exercise Date input (calendar test)
October 31, 2026
Alternative trigger date for Series A Common Warrant Initial Exercise Date
Maximum termination date for Series A Common Warrants
November 30, 2026
Latest possible Series A Common Warrant Termination Date
Series A Warrant exercise window
30 days
Period after Initial Exercise Date during which warrants are exercisable
Key Terms
Phase 3 ELAINE-3 clinical trial, CDK4/6 inhibitor, ESR1-mutated metastatic breast cancer, cashless net exercise, +2 more
6 terms
Phase 3 ELAINE-3 clinical trial medical
"enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial"
CDK4/6 inhibitor medical
"lasofoxifene in combination with abemaciclib, a CDK4/6 inhibitor"
A CDK4/6 inhibitor is a type of cancer drug that blocks two proteins (CDK4 and CDK6) that tell cells to divide, effectively slowing or stopping the growth of tumors. Think of it as cutting power to a photocopier that keeps making cancer cells; that control can shrink tumors or delay progression. For investors, these drugs matter because clinical trial results, regulatory approvals, patent life, safety issues and competition directly affect sales potential and company value.
ESR1-mutated metastatic breast cancer medical
"as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer"
cashless net exercise financial
"will be exercisable on a cashless net exercise basis"
complete response letter regulatory
"approves, or issues a complete response letter with respect to, the marketing application"
A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.
resale registration statement regulatory
"unless a resale registration statement registering the resale of the shares"
A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.
FAQ
What milestone did LeonaBio (LONA) announce for the ELAINE-3 trial?
LeonaBio announced enrollment of the 500th subject in its Phase 3 ELAINE-3 clinical trial of lasofoxifene plus abemaciclib for ER+, HER2-negative, ESR1-mutated metastatic breast cancer after prior aromatase inhibitor and CDK4/6 inhibitor therapy.
How many Series A Common Warrants has LeonaBio (LONA) issued and at what price?
LeonaBio has issued 23,031,494 Series A Common Warrants, each with an exercise price of $6.35 per share, generally payable in cash unless a resale registration statement is unavailable, in which case they are exercisable on a cashless net basis.
When do LeonaBio’s (LONA) Series A Common Warrants become exercisable?
The Series A Common Warrants become exercisable after the earlier of (1) the latest of June 30, 2026, the publicly announced ELAINE-3 Enrollment Date, and specified FDA action on imlunestrant plus abemaciclib, and (2) October 31, 2026.
How long will LeonaBio’s (LONA) Series A Common Warrants remain exercisable?
The Series A Common Warrants remain exercisable for 30 days after the Initial Exercise Date, with the termination date no later than November 30, 2026, at each holder’s option.
How much capital could LeonaBio (LONA) receive if all Series A Warrants are exercised?
If all 23,031,494 Series A Common Warrants are exercised for cash at $6.35 per share, LeonaBio states it would receive approximately $146.2 million of additional capital.
What risks does LeonaBio (LONA) highlight regarding the Series A Warrant proceeds?
LeonaBio notes that some or all Series A Common Warrants may expire unexercised or be exercised on a cashless net exercise basis, which could result in reduced or no cash proceeds to the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
